Open Access 2.0

Open Access 2.0 © Grant Faint/Getty Images The nautilus: where - and how - OA will actually work By Joseph J. Esposito Related Articles The nautilus model of scientific publishing OA, OK? The debate over open access to the scientific literature appears to be moving onto a new phase. Many continue to argue one side or the other of a binary choice: Either all research publishing should be open access, or only traditional publishing can maintain

| 13 min read

Register for free to listen to this article
Listen with Speechify
0:00
13:00
Share

By Joseph J. Esposito

The nautilus model of scientific publishing

OA, OK?

The debate over open access to the scientific literature appears to be moving onto a new phase. Many continue to argue one side or the other of a binary choice: Either all research publishing should be open access, or only traditional publishing can maintain peer review and editorial integrity. Others, however, have moved beyond that false dichotomy, instead increasingly seeing various hybrid models emerging and new, often complex, business arrangements.

Partly this is a product of the apparent inability of open-access ventures to produce economically sustainable models. It is unclear whether BioMed Central, a privately held sister company of The Scientist, has broken even, and the Public Library of Science tax return from the fiscal year ending September 30, 2006, the most recent publicly available, indicates that the organization lost $1.4 million on $5 million in revenue. Even ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Joseph J. Esposito

    This person does not yet have a bio.

Published In

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics
Optimize PCR assays with true linear temperature gradients

Applied Biosystems™ VeriFlex™ System: True Temperature Control for PCR Protocols

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo